Loading…
← CockpitCompetitor Analysis › 688765.SS Wuhan Healthgen Biotechnology Corp Class AOpen in the cockpit ↗

Wuhan Healthgen Biotechnology Corp Class A688765.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese biotech developing plant-based (rice) recombinant human serum albumin and other recombinant proteins.

≈ A niche plant-made-biologics companyMomentum laggard 11
Mkt cap
$1.46B
US dollars, full cap
Free float
94%
of shares outstanding
$/day
$33.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-15.4 pp
WACC 11.7%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥28.23
1D-2.5%
1W-15.1%
1M-14.7%
3M-28.6%
6M-50.7%
YTD-59.1%
1Y-78.0%
ATR %8.0%
52w lowhigh78.1% off high

What Wuhan Healthgen Biotechnology does

Chinese biotech developing plant-based (rice) recombinant human serum albumin and other recombinant proteins.

In one line: A niche plant-made-biologics company.

Products and services

  • Recombinant human serum albumin (rice-derived)
  • Other recombinant proteins

Customers

  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Biopharmaceuticals
  • Plant-made recombinant proteins

What could go right

  • Albumin import substitution
  • Novel manufacturing platform adoption

What could go wrong

  • Regulatory approval/commercialization risk
  • Small scale versus plasma-derived incumbents

Moat: narrow (IP / patents, process know-how). Proprietary rice-seed bioreactor platform for producing recombinant albumin, a novel manufacturing route.

Headquarters: Wuhan, China · Employees: 253

Named competitors

Wuhan Healthgen Biotechnology at a glance

Size Wuhan Healthgen Biotechnology (688765.SS) is a China Health Care company (Biotechnology) with a market value of $1.46B, the 1556th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.23 on 18 Nov 2026.

Performance Over six months the shares fell 50.7%, against -17.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 89.8% over the last twelve months (peer median +20.3%); the operating margin is -297.1% (peer median -12.4%).

Valuation It trades at 205.0× enterprise value to sales against a peer median of 12.9× (5th most expensive of 17).

Capital Return on invested capital runs 15.4 points below its cost of capital (11.7% WACC).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 82688765.SS 50
Six months, rebased to 100: Wuhan Healthgen Biotechnology against the median of its 20 peers (local-currency closes).

Wuhan Healthgen Biotechnology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aCN¥47.9MCN¥25.2MCN¥22.4MCN¥12.6M
Revenue growth—+90%+12%+78%—
Gross profitn/a-CN¥33.2M-CN¥38.3M-CN¥28.3M-CN¥2.55M
EBITDAn/a-CN¥75.9M-CN¥105M-CN¥160M-CN¥150M
Net incomen/a-CN¥157M-CN¥151M-CN¥187M-CN¥144M
Free cash flown/a-CN¥666M-CN¥220M-CN¥224M-CN¥425M
Capital expendituren/aCN¥538MCN¥167MCN¥102MCN¥358M
Total debtCN¥369MCN¥368MCN¥223MCN¥93.9MCN¥15.2M

Quarterly statements and history in the cockpit →

Wuhan Healthgen Biotechnology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%URGN2637IMCRMSB688105087010ABSI688319ANABKRSARAPPPGEN688185NRIX4588TYRA688765.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Wuhan Healthgen Biotechnology is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×URGNIMCRMSBQURE087010ABSIKRSAPGENNRIX4588688765.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wuhan Healthgen Biotechnology is the large dot.

Wuhan Healthgen Biotechnology competitors and peer comparison

Head to head with its named competitors (688765.SS vs 002252.SZ vs 002007.SZ vs CSL.AX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Wuhan Healthgen Biotechnology 688765.SS$1.46B-51%+90%-297%205.0×n/a
Shanghai RAAS Blood Products 002252.SZ$4.57B-15%-22%17%5.4×n/a
Hualan Biological Engineering 002007.SZ$3.20B-17%-11%17%5.3×15.8%
CSL CSL.AX$63.7B+102%-2%26%4.8×6.8%

How Wuhan Healthgen Biotechnology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wuhan Healthgen Biotechnology against its 20 peers (data as of 18 Nov 2026)
Measure688765.SSPeer medianRank in peer set
1-month return-14.7%-10.2%10th lowest of 21
6-month return-50.7%-17.0%2nd lowest of 20
Distance from 52-week high-78.1%-45.9%2nd lowest of 21
Revenue growth (TTM)+89.8%+20.3%6th highest of 17
Operating margin-297.1%-12.4%7th lowest of 18
EV / Sales205.0×12.9×5th most expensive of 17
ROIC minus cost of capital-15.4 pp-14.4 pp6th highest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a

Questions

Who are Wuhan Healthgen Biotechnology's main competitors?
Named competitors: Shanghai RAAS Blood Products (002252.SZ), Hualan Biological Engineering (002007.SZ), CSL Behring (CSL.AX). The cockpit's measured peer set (industry) also includes UroGen Pharma (URGN), Fujian Haixi Pharmaceuticals (2637.HK), Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh (IMCR), Mesoblast (MSB.AX), Nanjing Vazyme Biotech (688105.SS), uniQure (QURE).
Is Wuhan Healthgen Biotechnology expensive compared with its peers?
On ev / sales it trades at 205.0× against a peer median of 12.9×, 5th most expensive of 17 in its peer set.
How has Wuhan Healthgen Biotechnology stock performed?
Over six months to 18 Nov 2026 the shares returned -50.7% against -17.0% for the median peer; over one year -78.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.